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ABSTRACT 
Objective: The purpose of this investigation was to study the influence of cyclodextrin complexation on development of sustained release bio-
adhesive repaglinide tablets for buccal delivery. Methods: Based on preliminary phase solubility studies, solid complexes prepared by freeze-drying 
method in 1:1 molar ratio were selected and characterized by Fourier transform infrared spectroscopy to corroborate the fact of complex 
formation. The sustained release repaglinide tablets were produced by direct compression and this drug or complexed –loaded hydrophilic matrices 
using HPMC, Sodium CMC and Carbopol as muco-adhesive polymers were assessed for in vitro bioadhesion strength, in vitro release modulation, 
surface pH, % moisture absorption and ex vivo permeation through porcine buccal membrane. Results: When the drug was incorporated as 
repaglinide-Hydroxypropyl-β-Cyclodextrin (HP-β-CD) freeze-dried product, total amount of drug permeated from the tablet through epithelium in 
about 12 hrs, displayed a constant release regimen after a transient period. The effect of HP-β-CD incorporation on the release mechanism was 
rationalized on the basis of the interplay of different physical phenomena: erosion and swelling of the tablet, drug dissolution, and complex 
formation. Formulation F10 showed % moisture absorption of 23.46 for 4hrs, surface pH 6.9±0.015, Peak detachment force 3.65±0.18 N, Work of 
adhesion 1.12±0.10 mJ, and in vitro drug release 98.31% in 6h. The feasibility of buccal administration of repaglinide was assessed by permeation 
experiments on excised mucosa of pig. The ex vivo permeation studies demonstrated that the matrix tablets containing repaglinide–HP-β-CD (F10) 
solid complex exhibited significantly higher drug permeation (92.18 % for 12hrs) compared to all of the other formulations tested, which could be 
attributed to both, the presence of the polymers, and the drug-cyclodextrin complexation. The flux was found to be increased by 1.12-1.37 folds with 
a permeability coefficient of 0.017-0.018. Conclusion: The results demonstrate that the formulations with inclusion complexes afford high utility as 
a trans-mucosal drug delivery system for improved drug release and permeability. 
Keywords: Repaglinide, Freeze drying, HP-β-CD complexation, Bioadhesion, Ex-vivo permeation, Solubility  
INTRODUCTION 
Buccal mucosa is a potential site for the delivery of drugs to the 
systemic circulation. A drug administered through the buccal 
mucosa enters directly into the systemic circulation, thereby 
minimizing the first-pass hepatic metabolism and adverse gastro-
intestinal effect [1]. However, permeability of drugs through oral 
mucosa is too low to allow plasma concentration to reach 
therapeutic levels. Buccal permeation can be improved by using 
various classes of transmucosal penetration enhancers such as bile 
salts, surfactants, fatty acids and derivatives, chelating agents and 
cyclodextrins[2].  
However, the design of buccal systems for poorly water-soluble 
drugs is a challenging issue. Lipophilic drugs, although being well 
absorbed through oral epithelia, exhibit too low flux due to a low 
chemical potential gradient, which is the driving force for transport. 
In this regard, cyclodextrins have emerged as an effective tool to 
increase drug release rate of sparingly soluble drugs once 
incorporated in sustained-release matrix-type systems made of 
different polymers [3]. These molecules are cyclic oligosaccharides 
with a hydrophilic outer surface and a hydrophobic central cavity. 
The hydrophilic exterior of the cyclodextrin molecules makes them 
water-soluble while the hydrophobic cavity provides a 
microenvironment for appropriate sized non-polar molecules [4]. CD 
can promote changes in erosion rate and hydrophilicity of the matrix 
[5], induce osmotic effects (observed in the case of polyionic CD) and 
pore formation [6], as well as modify drug effective mobility in the 
hydrated polymer [7]. 
The biopharmaceutical classification system (BCS) is used to group 
pharmaceutical actives depending upon the solubility and 
lipophilicity (permeability) characteristics of the drug.  BCS   class   II  
 
 
compounds are poorly soluble but highly permeable, and they 
exhibit bioavailability that is limited by dissolution rate. The 
dissolution rate of BCS class II drug substances may be accelerated 
by improvement of the wetting characteristics of the bulk powder. 
Repaglinide (BCS class II compound), a carbamoylmethyl benzoic 
acid derivative, is a new anti diabetic agent from the class of glinides, 
used for the treatment of patients with type 2 diabetes mellitus by 
stimulating insulin secretion from pancreatic beta-cells. The 
substance is characterized by very low water solubility and a high 
lipophilicity (logP = 3.97) [8]. Repaglinide, S (+)2-ethoxy-4(2((3-
methyl-1-(2-(1-piperidinyl) phenyl)- butyl) amino)-2-oxoethyl) 
benzoic acid, is chemically unrelated to the oral sulfonylurea insulin 
secretagogues (Figure 1). It is differentiated from other 
hypoglycemic agents such as sulphonyl ureas by its rapid and short 
duration of action. Following oral administration of repaglinide at 
clinically relevant doses, peak serum levels are reached within 30-60 
min. Repaglinide is almost completely (98%) bound to plasma 
proteins, has a low tissue distribution and undergoes a very rapid 
elimination from the body, with a plasma half-life of less than 1hr. 
The mean absolute bioavailability is 56%. Repaglinide is completely 
metabolized by oxidative biotransformation and direct conjugation 
with glucouronic acid after either an IV or oral dose. Metabolites do 
not contribute to the glucose-lowering effect of repaglinide. 
Maximum daily dose of Repaglinide is 16mg and needs to be 
administered 4 times a day to maintain plasma drug levels. Patient 
compliance is compromised due to frequent administration of the 
drug. Hence it was selected as a model for buccal drug delivery and 
as being a poorly soluble drug repaglinide was complexed with β-
cyclodextrins. 
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Figure 1: Chemical structure of repaglinide 
The purpose of this study is to evaluate the possibility of increasing 
the solubility of repaglinide through complexation with cyclodextrin. 
Lyophilization was used as suitable method for obtaining inclusion 
complexes between repaglinide and cyclodextrin. In an attempt to 
develop a buccal tablet for the delivery of a poorly water-soluble 
repaglinide, we designed a matrix system based on a blend of HPMC 
K4M, HPMC K15M, Sodium CMC and Carbopol 947P as bioadhesive 
sustained release platform and hydroxypropyl-β-cyclodextrin (HP-β-
CD) as modulator of drug release. In the first part of the study, we 
rationalized the effect of HP-β-CD on the release features of the 
system whereas in the second part we assessed the physicochemical 
parameters of repaglinide tablets as buccal delivery system. 
MATERIALS AND METHODS 
Materials  
Repaglinide was gift sample from Dr.Reddy’s laboratories, 
Hyderabad. Mannitol SD 200 was gift sample from Signet chemical 
corporation, Mumbai, India. Hydroxypropyl methyl cellulose (HPMC 
K4M, HPMC K15M), Sodium carboxy methyl cellulose and Carbopol 
947P were gift samples from Dr.Reddy’s laboratories, Hyderabad, 
India. All chemicals and reagents used were of analytical or 
pharmacopoeial grade. 
Calibration curve of Repaglinide 
Calibration curve for the estimation of the drug was constructed 
employing distilled water as medium (pH 7). The stock solution of 
the repaglinide (100µg/mL) prepared in methanol, was 
subsequently diluted with distilled water to obtain a series of 
dilutions containing 1, 2, 4, 6, 8, 10, 20 and 30 μg/mL of the drug. 
The absorbances of the above dilutions were measured using UV-
Visible spectrophotometer at λmax of 226nm. These Calibration 
curves were used for estimation of repaglinide in the present study. 
Phase solubility studies 
Phase solubility studies of pure drug repaglinide with different 
concentrations of Hydroxy propyl β-cyclodextrin (0.1-5 millimoles) 
were performed by the method described by Higuchi and Connors 
[9]. Briefly, excess amount of the drug was added to 10mL of double 
distilled water containing various concentrations of Hydroxy propyl 
β-cyclodextrin (0.1-5 mM) taken in a stoppered glass vials. The 
suspensions were vigorously shaken at 25 ± 1˚C for 3 days on a 
rotary shaker. After equilibrium was attained, the samples were 
filtered through a 0.45 µm Millipore membrane filter and suitably 
diluted. These samples were assayed for the drug content by UV- 
Visible spectrophotometer against blank in same concentration of 
HP-β-CD in water so as to cancel any absorbance that may be 
exhibited by the cyclodextrin molecules. The solubility experiments 
are conducted in triplicate.  
The apparent 1:1 stability constant, Ks, was calculated from the 
phase solubility diagrams using the equation: 
Ks= slope/S0 (1 − slope) 
where S0 is drug solubility in the absence of HP-β-CD (intercept). 
Preparation of Freeze–dried solid inclusion complexes 
Solid inclusion complexes were prepared by freeze-drying method. 
Systems were prepared in a stoichiometry 1:1 (drug:cyclodextrin) 
according to previous phase solubility studies [10]. 1mM 
cyclodextrin derivative was initially dissolved in distilled water and 
a 50% ethanolic solution containing repaglinide was then added 
stepwise to the aqueous solution of cyclodextrin derivative. It was 
stirred at 600 rpm for 6 hrs until a stable suspension was formed on 
magnetic stirrer to obtain complexation equilibrium. All the clear 
solutions were frozen at 2-8°C and the frozen solutions were 
lyophilized in a freeze-dryer (LYODEL) to obtain a solid complex for 
72 hrs. These inclusion complexes were subjected to FT-IR studies to 
corroborate the extent of complex formation. The drug content of 
freeze dried product was assayed to calculate the equivalent amount 
of repaglinide to be taken. 
FTIR spectroscopic studies for drug-excipient compatibility 
A Fourier Transform- Infra Red spectrophotometer (Spectrum BX 
series, 51658, Perkin Elmer BX, UK) equipped with spectrum v2.19 
software by KBr pellet method was used to characterize the drug-
excipient (binary mixture of drug: excipient 1:1 ratio) compatibility 
and extent of complexation.  The instrument was operated under dry 
air purge. A base line correction was made using dried potassium 
bromide and then the spectra of the dried mixture of drug, 
formulation mixture and potassium bromide were recorded on FTIR. 
The spectrum for each sample was recorded at scanning speed of 2 
mm/sec over the 4000-400 cm-1 spectral region with a resolution of 
4 cm-1[10]. 
Sustained release bioadhesive buccal tablets preparation 
The tablets were prepared by direct compression of the repaglinide 
(4mg) or repaglinide-cyclodextrin complex (5.25mg binary systems 
containing 4mg of repaglinide) with mucoadhesive polymers like 
HPMC, Sodium CMC and Carbopol 947P in various ratios. Mannitol 
SD 200, magnesium stearate and talc were used as filler and 
lubricants respectively. Each component previously screened 
through #100 mesh, were mixed and compressed on a 16 station 
rotary tablet compression machine (Riddhi, Ahmedabad, India) 
using 8 mm circular flat beveled punches. For comparison purpose 
tablets containing uncomplexed drug with similar composition were 
also prepared. The detailed compositions of repaglinide tablet 
formulations are given in Table 1. Each tablet (250 mg) contained 4 
mg of repaglinide, free or in complex form. 
Weight and thickness variation 
The weights of repaglinide buccal tablets were measured using 
digital balance (Denver, Germany). The average values and standard 
deviation were calculated. The thickness was measured using a 
digital screw gauge (Mitutoyo, Japan). Ten individual tablets from 
each batch were used and the average values were taken. 
Hardness Test 
Tablets require a certain amount of strength or hardness and 
resistance to withstand mechanical shocks. The hardness of tablet 
was measured by Pfizer hardness tester (Cadmach, India) and 
results were expressed in Kg/cm2. 
Assay of the tablets 
Ten tablets were taken and powdered; powder equivalent to one 
tablet was taken and was allowed to dissolve in the medium by 
sonication for 30min. The solution was centrifuged and the 
supernatant was filtered through 0.22µ membrane filter. The 
absorbance of filtrate was measured using a UV-Visible 
spectrophotometer (Elico, India) at 226 nm against blank by suitable 
dilutions and drug content was analyzed. 
In vitro dissolution studies 
Dissolution from the repaglinide-CD complex and plain repaglinide  
buccal tablets were evaluated in distilled water using USP XXIII 
dissolution apparatus type-II (8 stations, Tab machines, India) at 37 
± 0.5˚C stirring at 50 rpm. Dissolution studies of buccal tablets were 
performed using 500 mL of dissolution medium, by sticking the 
impermeable layer side onto the glass slide with the help of 
cyanoacrylate adhesive. 5mL samples were withdrawn at 
predetermined time intervals and analyzed spectrophotometrically 
at 226 nm against placebo tablet as blank. Results are reported as % 
released repaglinide fraction (ratio of released repaglinide to the 
total amount of repaglinide added to the medium) ±S.D. of three 
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replicates. The concentration of repaglinide in the surrounding 
medium was always below the saturation concentration by 
maintaining sink conditions.  
Data analysis 
In order to understand the mechanism and kinetics of drug release, 
the results of the in vitro drug release study were fitted to various 
kinetics equations like zero order (Time Vs Cumulative % release), 
first order (Time Vs log Cumulative % drug remaining), higuchi rate 
(Square root of time Vs cumulative % release), korsemeyer-peppas 
and release exponent (n) (log time Vs log cumulative % release). “n” 
value analyzed from slope of linear regression equation of Peppas 
represents the drug transport mechanism. n<0.5 indicates Fickian 
diffusion, 0.5<n<1 indicates non-fickian, n=1 indicates Case II 
transport and n> 1 indicates Super case II transport [11].  
Bioadhesion studies 
The bioadhesive parameters were determined at room temperature 
using a microprocessor based advanced force gauze with a 
motorized test stand, fitted with 5 kg load cell (Ultra Test, Mecmesin, 
West Sussex, UK) and equipped with a computer integrated data 
acquisition system. To the upper and the bottom support of the 
tensile apparatus two 15mm diameter aluminium discs were 
secured. The tablet was fixed to the lower support while the porcine 
buccal mucosa was fixed to the upper support by using a 
cyanoacrylate adhesive. The tablet was wetted with 0.1 mL of 1% 
mucin by using a micropipette. Then, the upper support was moved 
down at 30 mm/min and stopped when the force between the tablet 
and the mucosa was 2 N. After 10 min of contact, the crosshead 
moved upward at a speed of 0.5 mm/min. The peak detachment 
force (F) and the work of adhesion (W, area under the force/distance 
curve) were recorded. The temperature during the experiment was 
23˚C and relative humidity 46–50%. Results are the mean of three 
force–elongation experiments. 
Surface pH 
The surface pH of the buccal tablets was determined in order to 
investigate the possibility of any side effects in vivo. As an acidic or 
alkaline pH may cause irritation to the buccal mucosa, care was 
taken to keep the surface pH as close to neutral as possible. The 
method adopted by Battenberg et al., [12] was used to determine the 
surface pH of the tablet. A combined glass electrode was used for 
this purpose. The tablet was allowed to swell by keeping it in contact 
with 5 mL of distilled water (pH 6.5 ± 0.05) for 2hrs at room 
temperature. The pH was measured by bringing the electrode in 
contact with the surface of the tablet and allowing it to equilibrate 
for 1 min. 
Moisture absorption studies 
Moisture absorption study for prepared batches was carried by 
using weight gain method on an agar plate. Initially, 1% agar 
solution was prepared on a hot plate by continuous stirring. This 
was then poured into a petri plate and allowed to solidify by cooling. 
Then buccal tablets were weighed individually (W1) and placed 
separately in Petri dish. At regular 1- hour time intervals until 4 hrs, 
the tablet was removed from the Petri dish and excess surface water 
was removed carefully using filter paper. The swollen tablet was 
then reweighed (W2) and the % moisture absorbed were calculated 
according to the equation: 
% Moisture uptake = Final weight (W2) – Initial weight (W1) X 100  
                                                 Initial weight (W1) 
Porcine Buccal Tissue Preparation 
Porcine buccal mucosa was used as it resembles much better to the 
human buccal mucosa regarding permeability, barrier lipid 
composition, histology and ultra-structural organization [13]. Buccal 
mucosa from pigs weighing 70–100 kg was obtained freshly from a 
local slaughter house and it was used at least within 3 hrs after 
animal slaughtering. The mucosal membrane was excised by 
removing connective and adipose tissue and was equilibrated at 37 
± 0.1˚C for 30 min in distilled water. 
Ex vivo permeation study 
The porcine buccal mucosa was carefully mounted in between the 
two compartments of Modified Franz Diffusion cell [14], with a 
diffusion area of 3.58 cm2 and a compartment volume of 25 mL. The 
donor and the acceptor chambers were filled with distilled water at 
pH 7.0 ± 0.5 and allowed to equilibrate for 30 min. The donor 
chamber was emptied after the equilibration period and replaced 
with 3 mL of a solution containing 4mg of repaglinide alone, buccal 
tablets containing plain drug and buccal tablets containing 
complexed drug. The tablets were stuck to the mucosa in the donor 
side. Receiver medium was maintained at 37±0.1˚C under stirring of 
400 rpm on a magnetic stirrer. From the receiver compartment, 2 
mL aliquot was collected at predetermined time intervals and 
replaced by an equal volume of buffer solution. Analysis of samples 
was performed using a UV-Visible spectrophotometer at 226nm to 
determine the amount of drug permeated through the membrane. 
The repaglinide flux and permeability coefficient through the 
membrane was calculated using the equations: 
J = dQ/A.dt 
P= J/D 
Where J is the steady-state flux, A is the diffusion area, P is the 
permeability coefficient and D is the dose of drug in µg. 
RESULTS AND DISCUSSIONS 
The complexation of repaglinide with HP-β-CD, the effect of HP-β-CD 
on the solubility and the type of phase solubility diagram were 
investigated by phase solubility studies. All the phase solubility 
diagrams can be classified as type AL according to Higuchi and 
Connors. Because the straight line had a slope less than unity in each 
case, the increase in solubility was due to the formation of a 1:1 
molar complex in solution with drug. Thus the solubility of 
repaglinide was markedly enhanced by complexation with 1mM 
ratio of HP-β-CD and the results were indicated in Figure 2. 
 
Figure 2: Phase solubility studies of repaglinide in different 
milli molar ratios of HP-β-CD in water 
Freeze drying of solubilized repaglinide in cyclodextrin solution 
yielded a solid amorphous product. The assayed concentration of the 
drug in the solid product was found to be 98.9%. 
Further evidence of the complex formation was obtained by FT-IR 
spectroscopy. The infrared (FT-IR) spectra were obtained using a 
perkinelmer FT-IR spectrometer at resolution 4 cm-1 from 4000 to 
400 cm-1 (presented in Figure 3). The typical IR spectrum of pure 
repaglinide reveals the presence of a peak at 3309.22 cm-1, assigned 
to N-H stretching vibration and one at 1686.50cm-1, corresponding 
to the carbonyl group. Upon complexation, the repaglinide 
characteristic absorption peaks were not identified any more in the 
IR spectra or slightly shifted towards a lower wavenumber due to 
host-guest interactions, suggesting the formation of hydrogen bonds 
between the functional groups of repaglinide and the hydroxyl 
group of the host cavity. We consider the results obtained by IR 
Spectroscopy to serve as proof for the formation of inclusion 
complexes between HP-β-CD and repaglinide. Characteristic bands 
of repaglinide were well retained in the IR spectrum of drug-
polymer mixture without any new bands, indicating that there was 
no change in the structure of drug. On the basis of above report, it 
was concluded that repaglinide is compatible with polymers used. 
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Figure 3: FTIR spectrum of (A) Repaglinide pure drug (B) Repaglinide with HPMC (C) Repaglinide with Sodium CMC (D) Repaglinide- HP-
β-CD complexed freeze dried product 
In the present study, buccoadhesive tablets of repaglinide free or in 
the complex form were prepared with the objective of improving 
patient compliance by reducing frequency of administration.  A total 
number of fourteen formulations were prepared by four different 
bioadhesive polymers, HPMC K4M, HPMC K15M, Sodium CMC and 
Carbopol 947P containing the same amount of the drug alone or in 
the complexed form (Table 1). 
Table 1: Composition of various formulations of repaglinide 
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 
Repaglinide 4 - - 4 - - - 4 - - 4 - - - 
1mM FD Drug - 5.25 5.25 - 5.25 5.25 5.25 - 5.25 5.25 - 5.25 5.25 5.25 
Mannitol 216 206.75 214.75 220 222.75 218.75 210.75 208 198.75 206.75 220 226.75 218.75 210.75 
HPMC K4M 24 32 24 - - - - - - - - - - - 
HPMC K15 M - - - 20 16 20 28 - - - - - - - 
Sod CMC - - - - - - - 32 40 32 - - - - 
Carbopol 947P - - - - - - - - - - 20 12 20 28 
Magnesium 
stearate 
3 3 3 3 3 3 3 3 3 3 3 3 3 3 
Talc 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
*Freeze Dried Drug equivalent to 4mg Drug; All Amounts Represented in mg 
The results of weight variation, thickness, hardness and drug 
content of formulations were given in Table 2. The weights and 
thicknesses of tablets prepared by direct compression technique 
were within the limits as per IP specifications. A good content 
uniformity was observed among all the formulations. 
 
Table 2: Process parameters: Weight variation, Thickness, Hardness and drug content 
Formulation code Thickness (mm) Weight Variation(mg) Hardness (Kg/cm2) %Drug content 
F1 4.64±0.024 249±0.20 4.3±0.15 99.74 
F2 4.64±0.110 247±0.24 4.9±0.04 101.17 
F3 4.69±0.020 248.6±0.15 5.4±0.08 99.69 
F4 4.51±0.024 258.1±0.50 6.1±0.05 98.04 
F5 4.61±0.032 249.2±0.30 5.2±0.24 99.58 
F6 4.35±0.030 250.0±0.35 5.0 ±0.05 100.39 
F7 4.67±0.090 252.8±0.25 6.5±0.08 99.74 
F8 4.40±0.015 251.8±0.55 6.4±0.12 100.17 
F9 4.62±0.050 243.3±0.50 7.7±0.10 98.69 
F10 4.50±0.035 251±0.60 3.8±0.08 98.04 
F11 4.40±0.015 250.1±0.55 5.5±0.21 100.94 
F12 4.46±0.020 256.4±0.75 4.5±0.13 98.75 
F13 4.73±0.035 245.5±0.15 5.0±0.33 99.66 
F14 4.64±0.010 251.4±0.20 5.5±0.13 99.62 
*All the values are expressed as mean, n=10 
In vitro dissolution profiles of various formulations prepared are 
shown in Figure 4a & 4b. Differences in the drug release rate from 
the tablets can be attributed to the presence of different polymers 
(HPMC K4M, HPMC K15M, Sodium CMC and Carbopol 947 P) and 
cyclodextrin. Dissolution of pure drug based tablets was slower 
compared to the tablets containing the cyclodextrin complex. The 
drug complex dissolves easily in a hydrated polymeric environment, 
resulting in a higher diffusional driving force and faster drug release. 
Due to poor aqueous solubility, only a limited amount of drug can 
dissolve inside the hydrated polymeric matrices. Incorporation of 
HP-β-CD in the matrix improved the drug solubility and dissolution 
rate. The dissolved HP-β-CD in the gel matrix formed a complex with 
drug, and improved its solubility. The solubilization due to the in situ 
complex formation was the main reason for enhanced drug release 
from HP-β-CD containing polymeric matrices. 
 
Figure 4a: Comparative in vitro drug release profiles (F1-F7) of 
repaglinide buccal tablets 
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Figure 4b: Comparative in vitro drug release profiles (F8-F14) 
of repaglinide buccal tablets 
From the in vitro dissolution results, formation of inclusion 
complexes by freeze-drying technique showed a dramatic 
improvement in drug dissolution efficiency (84.68%, 71.58%, 
98.31% and 102.36% in 6hrs) against the pure drug (75.05%, 
62.66%, 86.62% and 84.95% in 6hrs) with various hydrophilic 
polymers like HPMC K4M (1:6), HPMC K15 M (1:5), sodium CMC 
(1:8) and carbopol 947P (1:5) respectively. The differences 
observed in drug release as a function of the type of polymer and 
cyclodextrin complexation were related to the differences in water 
absorption and erosion behavior of the tablets in the release 
medium. On the basis of these results obtained in the preliminary 
screening studies, the batches containing drug: HPMC K4M in the 
ratio of 1:6, drug: HPMC K15M in the ratio of 1:5 and drug: sodium 
CMC in the ratio of 1:8 showed the better drug release profile. Hence, 
they were selected for further studies. 
In the formulations optimized (F3, F6, F10 and F13), a Higuchi’s 
square root of time equation showed a significantly better fit than 
other equations (Table 3). The dissolution data were analyzed for 
release mechanism using the equation proposed by Korsmeyer. In 
the optimized tablets containing only HPMC, the values of ‘n’ were 
0.18-0.35 indicating that the transport of drug from the tablets was 
governed by Fickian mechanism whereas for the optimized 
formulation containing sodium CMC, the value of ‘n’ was 0.60. Finally 
the formulation containing carbopol 947P has ‘n’ value of 0.96, 
which is indicative of anomalous or non-Fickian release, i.e. the drug 
release proceeded by diffusion as well as erosion of the polymer and 
hence excluded from the study.  
Table 3: Release kinetics and correlation coefficients of repaglinide buccal tablets 
Formulation Code Zero order R2 First order R2 Higuchi R2 Korsemeyer-Peppas R2 n –value 
F1 0.7856 0.8778 0.9428 0.8905 0.4532 
F2 0.8464 0.9386 0.9602 0.9544 0.5094 
F3 0.649 0.8294 0.9709 0.8669 0.187 
F4 0.9169 0.9704 0.976 0.9294 0.6579 
F5 0.6014 0.7049 0.8523 0.9576 0.1812 
F6 0.7844 0.8958 0.9503 0.9167 0.3586 
F7 0.9641 0.9708 0.8945 0.8048 1.4829 
F8 0.9363 0.9526 0.9457 0.9674 0.7882 
F9 0.878 0.9802 0.9606 0.9263 0.5872 
F10 0.8247 0.925 0.9395 0.8747 0.6078 
F11 0.9591 0.9855 0.9174 0.9383 1.1249 
F12 0.9974 0.9374 0.8917 0.9994 1.0523 
F13 0.9508 0.943 0.9529 0.9322 0.9608 
F14 0.8806 0.9657 0.9905 0.9177 0.398 
An overall evaluation of the mucoadhesive behaviour of optimized 
formulations on pig buccal mucosa was performed by determining 
the force of detachment (N) versus time. Swelling of the polymer 
contributed to the interpenetration of mucus and made bioadhesion 
possible [15]. Adhesion tests (detachment force and the work of 
adhesion) for the formulations optimized are shown in Table 4. The 
bioadhesive forces of buccal tablets were affected by the nature of 
the polymer. The peak detachment force was considered to be 
dependent on the formation of hydrogen bonds between the 
functional groups of the bioadhesive and the mucus. The 
bioadhesive behavior of the tablets has been characterized by means 
of the work of adhesion, W, i.e. the area under the force–elongation 
curve. HPMC alone had poor adhesive properties.  It was evident 
that the peak detachment force and the work of adhesion values 
increased in the presence of Sodium CMC and Carbopol 947P in the 
tablets due to increased physical entanglement, producing a broader 
force/distance curve, and thus increased the work of adhesion 
values. Considering the overall properties of complexed drug 
containing tablets, it can be concluded that the formulations 
containing HPMC K4M, HPMC K15M, Sodium CMC, Carbopol 947P 
display good bioadhesive properties, although containing 
considerable amounts of HP-β-CD, and are suitable for transmucosal 
applications. 
Table 4: Bioadhesive strength parameters and surface pH values of optimized formulations 
Formulation code Peak detachment force(N) Work of adhesion(mJ) Surface pH 
F3 2.30±0.06 0.540±0.13 6.8±0.010 
F6 3.08±0.03 0.743±0.11 6.8±0.515 
F10 3.65±0.18 1.12±0.10 6.9±0.015 
F13 4.62±0.17 1.33±0.14 6.7±0.515 
*All the values are expressed as mean, n=3 
The surface pH of the buccal tablets was determined in order to 
investigate the possibility of any side effects in vivo. As an acidic or 
alkaline pH may cause irritation to the buccal mucosa, it was 
determined to keep the surface pH as close to neutral as possible. 
Surface pH of the optimized formulations was found to be 6.7±0.515 
to 6.9±0.015 as presented in Table 4. The pH was found to be near to 
the neutral. From the results it was found that, the formulation does 
not cause any irritation to the buccal mucosa.  
Appropriate swelling property of a buccal device is essential for 
uniform and prolonged release of drug and proper mucoadhesion 
[16]. All the formulations showed an increase in weight due to water 
uptake. The % moisture absorption of the prepared buccoadhesive 
tablets showed moisture absorption rates in the order: F13 > F10 > 
F3 > F6 (Table 5). The high uptake of water in the case of the F13 
may be due to the faster hydration rate of polymers. This could be 
attributed to the Carbopol property to retain water and form a thick 
swollen mass. HP-β-CD also promoted hydration of the polymeric 
system acting as a channeling or wicking agent. The tablet 
formulated with sodium CMC (F10) rapidly absorbed water and 
showed a higher degree of swelling compared to the tablet 
formulated with HPMC (F3, F6). Ionization of carboxylic groups of 
polymer with subsequent repulsion and relaxation of the polymer 
chains resulted in an increase of water uptake and hence of the % 
moisture absorption with time. The presence of phosphate ions 
retarded the HPMC hydration [17]. Formulations with carbopol and 
sodium CMC showed higher % moisture absorption values, this is 
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because the water swellable polymers can absorb more water and swell to higher extent than that of water insoluble polymers.  
Table 5: Percentage of moisture absorption of optimized repaglinide buccal tablets 
Time (hrs) % Moisture absorbed 
F3 F6 F10 F13 
0.25 2.29±0.15 2.27±0.07 1.15±0.24 18.3±0.96 
0.5 2.68±0.34 3.4±0.05 3.07±0.10 25.67±0.61 
1 4.98±0.09 4.92±0.13 6.5±0.06 55.17±0.21 
2 10.72±0.11 8.56±0.51 13.4±0.34 69.34±0.54 
3 17.24±0.26 14.39±0.19 20±0.21  
4 21.83±0.42 16.66±0.28 23.46±0.18  
*All the values are expressed as mean, n=3 
Physicochemical, swelling and erosion, bioadhesion properties for 
these formulations were studied and the results revealed that the 
optimized formulations (F3, F6 & F10) demonstrated good 
bioadhesion with acceptable moisture absorption ratio. Hence, they 
were selected for the ex vivo permeation studies through porcine 
buccal mucosa. 
Ex vivo permeability studies are a useful tool to assess the potential 
of a localized anatomical site as a route for drug delivery. However, 
ex vivo conditions should simulate the in vivo situation as closest 
possible. The permeation test was aimed at investigating the drug 
passage through the semipermeable membrane to which the tablets 
adhered. Ex vivo permeation study of Repaglinide drug solution 
containing 4mg of repaglinide alone, buccal tablets containing plain 
drug and buccal tablets containing complexed drug through the 
porcine buccal mucosa was performed using Modified Franz 
diffusion cell and membrane assembly,  at 37°C ± 0.5°C and 400 rpm 
by using  magnetic stirrer. The samples were collected at 
predetermined time intervals (0.5, 1.0, 1.5, 2.0, 3.0, 4, 6, 8, 10 and 
12hrs) and the analysis was carried out to determine the drug 
permeated.   
In the investigation of integrity of buccal mucosa, Phenol red was 
used as marker compound and is not expected to permeate through 
the porcine membrane. Absence of phenol red in the receiver 
compartment indicated the intactness of the buccal membrane. This 
data suggests that the tissue could be isolated successfully and 
integrity of buccal mucosa was maintained during the permeation 
studies. The principle here is that phenol red being a very large 
molecule, cannot permeate the buccal mucosa and enter the 
acceptor chamber unless the mucosa is damaged. 
Table 6: Ex vivo parameters of repaglinide buccal tablets through porcine buccal mucosa 
Parameters  Cumulative amount of percentage drug permeated 
Drug solution With HPMC K4M With HPMC K15M With Sodium CMC 
F1 F3 F4 F6 F8 F10 
Flux (μg.hr-1 cm-2) 90 64.12 72.05 51.54 70.92 57.11 75.02 
Permeability coefficient (P) 0.022 0.016 0.018 0.012 0.017 0.014 0.018 
*All the values are expressed as mean, n=3 
The profiles of drug permeation from the buccal tablets are shown in 
Table 6 & Figure 5. Flux values were determined from the steady 
state region of the diffusion profiles obtained using the linear 
regression analysis. The differences in the plot of drug permeated 
and flux values of repaglinide from the tablets could be attributed to 
the polymers used, and the presence of HP-β-CD. The cumulative % 
of drug permeated from formulation F3 containing complexed 
repaglinide with HPMC K4M over 12 hrs through epithelium was 
90.13% and was greater than the % of drug permeated from 
formulation F1 containing plain drug alone. Formulation F6 
containing complexed repaglinide with HPMC K15M showed an 
increase in cumulative % drug permeated from 55.50% to 85.28% 
when compared to the formulation F4 containing  plain drug. At the 
end of 12hrs, the cumulative % drug permeated was 81.13% and 
92.18% from plain tablets (F8) and tablets containing complexed 
repaglinide with Sodium CMC (F10) respectively. This effect, in 
principle, can be attributed to an increase of driving force for 
permeation due to the increase of drug apparent solubility in the 
presence of HP-β-CD as well as to an enhancing effect of HP-β-CD. 
Cyclodextrins have been suggested to act as penetration enhancers. 
They enhance the permeation of the drug by carrying the drug 
through the aqueous barrier towards the surface of the membrane, 
where the drug passes from the complex into the membrane. 
Addition of HP-β-CD to the matrix increased the flux by increasing 
the solubility of drug, thus improving the diffusible form of the drug 
species at the tablet membrane interface. The flux was found to be 
increased by 1.12-1.37 folds with a permeability coefficient of 0.017-
0.018. Higher penetration rate of medium into the complex 
containing tablets may also contribute to the improved release rate. 
The drug was released gradually from the formulations over a 
period of 12hrs. The formulation comprising repaglinide-HP-β-CD 
complex and sodium CMC (RT10) demonstrated a complete and 
sustained release associated with an enhanced buccal permeation 
characteristics. 
 
Figure 5: Comparative ex vivo drug release profiles of 
repaglinide buccal tablets through porcine buccal mucosa 
CONCLUSIONS 
In conclusion, the influence of HP-β-CD on the drug release from 
buccal tablets was investigated in order to overcome the formulation 
problems connected with the design of sustained release systems 
containing poorly soluble drugs. Results of characterization of freeze 
dried system revealed that the formation of inclusion complex 
between repaglinide and HP-β-CD has improved its solubility and 
dissolution rate. Buccal tablets formulated with swellable 
hydrophilic polymer Sodium CMC containing complexed repaglinide 
showed better drug dissolution and permeability across buccal 
mucosa as compared to those containing plain drug.  
Repaglinide was released from the polymer matrices in a constant 
mode over the passage of time, thus providing a prolonged effect. 
Thus it can be concluded that the incorporation of cyclodextrins in a 
sodium CMC-based hydrophilic matrix intended for the delivery of 
poorly soluble drug repaglinide can be a suitable strategy to 
optimize the release features of the system while maintaining good 
bioadhesive properties. Along with avoidance of first pass 
metabolism, incorporation of complex into buccal tablet may lead to 
increased bioavailability of repaglinide. 
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